Cargando…
The role of tazemetostat in relapsed/refractory follicular lymphoma
Large strides have been made in the treatment of follicular lymphoma (FL) over the last few years. Although the majority of patients respond to upfront therapy, many experience disease progression with a progressive shortening of subsequent treatment free intervals. New treatment options are therefo...
Autores principales: | von Keudell, Gottfried, Salles, Gilles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165870/ https://www.ncbi.nlm.nih.gov/pubmed/34104370 http://dx.doi.org/10.1177/20406207211015882 |
Ejemplares similares
-
Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat
por: Raychaudhuri, Ruben, et al.
Publicado: (2022) -
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
por: Munakata, Wataru, et al.
Publicado: (2021) -
Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score–matched analysis of E7438-G000-101 trial outcomes
por: Proudman, David G., et al.
Publicado: (2022) -
Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan
por: Izutsu, Koji, et al.
Publicado: (2021) -
P1109: TRIAL IN PROGRESS: PHASE 1B/2 TRIAL OF TAZEMETOSTAT IN COMBINATION WITH VARIOUS TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
por: Bessudo, A., et al.
Publicado: (2022)